These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17401297)

  • 21. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abdominal obesity is associated with ineffective control of cardiovascular risk factors in primary care in France.
    Dallongeville J; Bringer J; Bruckert E; Charbonnel B; Dievart F; Komajda M; Pouchain D; Amouyel P
    Diabetes Metab; 2008 Dec; 34(6 Pt 1):606-11. PubMed ID: 19019717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medications to reduce cardiovascular risk after kidney transplantation.
    Swift PA; Andrews PA
    Transplantation; 2011 Mar; 91(5):492-3. PubMed ID: 21183866
    [No Abstract]   [Full Text] [Related]  

  • 25. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unhealthy lifestyle, statins and the secondary prevention of cardiovascular disease.
    Mascitelli L; Pezzetta F
    Intern Med J; 2007 Jun; 37(6):427-8. PubMed ID: 17535398
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of obesity and bariatric surgery on cardiovascular disease.
    Mathier MA; Ramanathan RC
    Med Clin North Am; 2007 May; 91(3):415-31, x-xi. PubMed ID: 17509386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Enlarged waist circumference and cardiovascular risk factors].
    Pataky Z; Bobbioni-Harsch E; Makoundou V; Golay A
    Rev Med Suisse; 2009 Mar; 5(196):671-2, 674-5. PubMed ID: 19462610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abdominal obesity and the spectrum of global cardiometabolic risks in US adults.
    Ghandehari H; Le V; Kamal-Bahl S; Bassin SL; Wong ND
    Int J Obes (Lond); 2009 Feb; 33(2):239-48. PubMed ID: 19050677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is it time to stop treating dyslipidaemia with fibrates?
    Benatar JR; Stewart RA
    N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.
    Gazzaruso C; Solerte SB; Pujia A; Coppola A; Vezzoli M; Salvucci F; Valenti C; Giustina A; Garzaniti A
    J Am Coll Cardiol; 2008 May; 51(21):2040-4. PubMed ID: 18498958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factor management: antiatherogenic therapies.
    Gielen S; Sandri M; Schuler G; Teupser D
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S29-36. PubMed ID: 19675434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-fat or low-carbohydrate diet for cardiovascular health.
    Best D; Grainger P
    Can J Cardiovasc Nurs; 2007; 17(3):19-26. PubMed ID: 17941565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
    Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM
    Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic determinants of response to statins.
    Peters BJ; Klungel OH; de Boer A; Maitland-van der Zee AH
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):977-83. PubMed ID: 19673675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity surgery: evidence for diabetes prevention/management.
    Cummings S; Apovian CM; Khaodhiar L
    J Am Diet Assoc; 2008 Apr; 108(4 Suppl 1):S40-4. PubMed ID: 18358255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using statins to reduce cardiovascular risk after carotid endarterectomy.
    Floros G; Anagnostou V; Tsiga E; Ferenidou F; Papadimitriou D
    Evid Based Cardiovasc Med; 2006 Mar; 10(1):1-4. PubMed ID: 16530653
    [No Abstract]   [Full Text] [Related]  

  • 40. Long term persistence with statin treatment in daily medical practice.
    Mantel-Teeuwisse AK; Goettsch WG; Klungel OH; de Boer A; Herings RM
    Heart; 2004 Sep; 90(9):1065-6. PubMed ID: 15310708
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.